Arsanis closes Series A financing
Arsanis, a new biotechnology company that develops anti-infective monoclonal antibody therapeutics, has closed a Series A financing with a total funding of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.
The financing involved equal contributions from OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences. Managing Partners Carl Gordon, Terry McGuire and Mike Ross have joined the founders on Arsanis’ board of directors.